Company intelligence / Profile preview

LENSAR

Orlando, Florida, United Stateslensar.com ↗

Ownership: Public · LNSR
Employees: ~140
Development stage: Commercial

Overview

The company’s femtosecond laser systems—including the ALLY Adaptive Cataract Treatment System—are FDA-cleared and commercially available. These platforms integrate augmented reality imaging for precise lens fragmentation and astigmatism management. Clinical adoption has been strong, with positive feedback from surgeons regarding workflow efficiency and patient outcomes. Revenue growth has been robust in recent years as market penetration increases.

Therapeutic areas: Ophthalmology
Modalities: DeviceMedical laser systemAugmented reality-assisted imaging system
Industry: Surgical Medical Devices

Partnerships

Strategic partnership/acquisition by Alcon announced March 2025

Financials

Market cap: $105.6M
Total revenue: $16.5M
Enterprise value: $94.4M

Beyond the preview

Go deeper on LENSAR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LENSAR.

Explore the full profile